Namibia - englanti - Namibia Medicines Regulatory Council

pharmafrica (pty) ltd - acetazolamide 250mg - tablet - each tablet contains: acetazolamide 250mg

Malesia - englanti - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

zulat pharmacy sdn. bhd. - acetazolamide -

Japani - englanti - すりの適正使用協議会 RAD-AR Council, Japan

sanwa kagaku kenkyusho co.,ltd. - acetazolamide - slightly yellowish white powder

Australia - englanti - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium valproate, quantity: 40 mg/ml - oral liquid - excipient ingredients: purified water; sorbitol solution (70 per cent) (non-crystallising); sodium methyl hydroxybenzoate; citric acid; brilliant scarlet 4r; hyetellose; sodium propyl hydroxybenzoate; saccharin sodium; flavour - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate

Australia - englanti - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - metformin hydrochloride, quantity: 500 mg; glibenclamide, quantity: 5 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; povidone; magnesium stearate; microcrystalline cellulose; titanium dioxide; lactose monohydrate; hypromellose; quinoline yellow; iron oxide yellow; iron oxide red; macrogol 4000 - second line treatment of diabetes mellitus type ii in adult patients whose glycaemic control is inadequate after diet and exercise alone and where combined therapy with metformin and glibenclamide is appropriate.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - metformin hydrochloride, quantity: 500 mg; glibenclamide, quantity: 2.5 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; povidone; magnesium stearate; microcrystalline cellulose; titanium dioxide; lactose monohydrate; hypromellose; iron oxide yellow; iron oxide red; macrogol 4000; iron oxide black - second line treatment of diabetes mellitus type ii in adult patients whose glycaemic control is inadequate after diet and exercise alone and where combined therapy with metformin and glibenclamide is appropriate.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - metformin hydrochloride, quantity: 250 mg; glibenclamide, quantity: 1.25 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; povidone; magnesium stearate; microcrystalline cellulose; titanium dioxide; lactose monohydrate; hypromellose; purified talc; iron oxide yellow; macrogol 4000 - second line treatment of diabetes mellitus type ii in adult patients whose glycaemic control is inadequate after diet and exercise alone and where combined therapy with metformin and glibenclamide is appropriate.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium valproate, quantity: 100 mg - tablet, uncoated - excipient ingredients: magnesium stearate; silicon dioxide; kaolin; maize starch - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate

Australia - englanti - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium valproate, quantity: 40 mg/ml - oral liquid - excipient ingredients: sorbitol; sodium propyl hydroxybenzoate; sodium methyl hydroxybenzoate; saccharin sodium; brilliant scarlet 4r; purified water; sucrose; flavour - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate

Australia - englanti - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium valproate, quantity: 500 mg - tablet, enteric coated - excipient ingredients: citric acid monohydrate; hypromellose; polyvinyl acetate phthalate; diethyl phthalate; purified talc; hyprolose; titanium dioxide; povidone; magnesium stearate; amaranth aluminium lake; calcium silicate; indigo carmine aluminium lake; stearic acid; macrogol 6000 - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate